CD19 and acute lymphoblastic leukemia: Clinical studies were also conducted using fourth-generation anti-CD19-CAR (4SCAR19) T cells containing a combination of three costimulatory domains, and these CAR T cells showed long-term high efficiency and safety in B-ALL patients (17).